Ken Jacobson is a California-based journalist who has been a reporter and editor for a number of publications covering business, economics, and technology, and from 2007 to 2011 served as an investigator on the Democratic staff of U.S. House of Representatives’ Science and Technology Committee. He has been chief editor of two specialized newsletters, New York-based Metals Week and DC-based New Technology Week, and senior editor of a third, Manufacturing and Technology News, also based in DC; a former foreign correspondent, he reported from Paris for BusinessWeek and from Amsterdam for the Associated Press. He has also contributed to a half-dozen published reports of the National Academies’ Board on Science, Technology, and Economic Policy, and authored the 1994 book Embattled Selves: An Investigation into the Nature of Identity Through Oral Histories of Holocaust Survivors. A graduate of the University of California at Berkeley, he currently resides in nearby Alameda.
By this expert
Pharmaceutical drugs are often a matter of life or death. It should be a prime objective of government policy to rid the industry of financialization.
Price gouging in the US pharmaceutical drug industry goes back more than three decades.
The company’s focus on stock buybacks to increase shareholder value is a reminder of why so much of the value created daily by millions of workers ends up in the hands of the billionaires